BiotechTube

Mavrilimumab + Placebo

Phase 2Completed
1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

COVID 19

Conditions

COVID 19, SARS-CoV 2, Pneumonia

Trial Timeline

May 20, 2020 → Nov 16, 2020

NCT ID
NCT04492514

About Mavrilimumab + Placebo

Mavrilimumab + Placebo is a phase 2 stage product being developed by Kiniksa Pharmaceuticals for COVID 19. The current trial status is completed. This product is registered under clinical trial identifier NCT04492514. Target conditions include COVID 19, SARS-CoV 2, Pneumonia.

What happened to similar drugs?

11 of 20 similar drugs in COVID 19 were approved

Approved (11) Terminated (7) Active (6)
✅mRNA-1283.251 Variant-containing FormulationModernaApproved
✅Icosapent ethylAmarin CorporationApproved
✅bamlanivimabEli LillyApproved
✅AZD1222AstraZenecaApproved
✅AZD1222AstraZenecaApproved
✅COVID-19 vaccine Pfizer (3 doses) + COVID-19 vaccine Pfizer (2 doses) + COVID-19 mRNA Vaccine Moderna (3 doses) + COVID-19 mRNA Vaccine Moderna (2 doses) + COVID-19 mRNA Vaccine Moderna (1 dose)SanofiApproved
✅Rivaroxaban 10 mgBayerApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04492514Phase 2Completed

Competing Products

20 competing products in COVID 19

See all competitors
ProductCompanyStageHype Score
mRNA-1283.251 Variant-containing FormulationModernaApproved
0
mRNA-1283.222ModernaPhase 3
0
COVID-19 VaccineModernaPreclinical
0
mRNA-1083ModernaPhase 3
0
SPIKEVAX (mRNA-1273)ModernaPreclinical
0
Moderna COVID-19 VaccineModernaPreclinical
0
Gam-COVID-VacDr. Reddy's LaboratoriesPhase 2/3
31
AVIGAN + Placebo ComparatorDr. Reddy's LaboratoriesPhase 3
29
Favipiravir + NitazoxanideStrides PharmaPhase 2
35
Human COVID-19 immunoglobulin (pH4) for intravenous injection + PlaceboSinopharmPhase 2
31
mavrilimumabKiniksa PharmaceuticalsPhase 2/3
32
Mavrilimumab + PlacebosKiniksa PharmaceuticalsPhase 2
29
Mavrilimumab + PlacebosKiniksa PharmaceuticalsPhase 2
29
Gimsilumab + PlaceboRoivant SciencesPhase 2
32
Icosapent ethylAmarin CorporationApproved
25
Icosapent ethylAmarin CorporationPhase 2
25
Bamlanivimab + Placebo + EtesevimabEli LillyPhase 3
40
GX-03 + Petrolatum ointmentTurn TherapeuticsPhase 2
25
Cytotoxic T LymphocytesTevogen BioPhase 1
19
InfliximabCelltrionPhase 2
35